HilleVax Targets $100 Million IPO For Acute Gastroenteritis Vaccine

Apr. 13, 2022 1:39 PM ETHilleVax, Inc. (HLVX)1 Like


  • HilleVax has filed to raise $100 million in an IPO, although the final figure may differ.
  • The firm is developing a vaccine for acute gastroenteritis.
  • HLVX has strong investor and technology backing in Takeda Pharmaceutical and Frazier Life Sciences.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »

Caucasian Scientists use microscopes to research the covid-19 virus vaccine in a medical laboratory

Godji10/iStock via Getty Images

A Quick Take On HilleVax

HilleVax (NASDAQ:HLVX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is a clinical-stage biopharma developing a vaccine for the prevention of acute gastroenteritis [AGE] caused by norovirus infection.

HLVX is a promising mid-stage company with top-tier investment backing, so the IPO could be interesting for patient life science investors.

I'll provide an update when we learn the IPO's pricing and valuation assumptions from management.

Company & Technology

Boston, Massachusetts-based HilleVax was founded to advance a pipeline of vaccine candidates to prevent acute gastroenteritis in infants, children, adults and older adults.

Management is headed by Chairman, President and CEO Rob Hershberg, M.D., Ph.D., who has been a venture partner at Frazier Healthcare Partners and prior to that was Executive Vice President of Business Development and Global Alliances of Celgene Corporation.

The firm's lead candidate, HIL-214, is in Phase 2 trials across all four age ranges and is preparing to enter Phase 3 trials for adults between 18 and 59 years old.

Below is the current status of the company's drug development pipeline:

HilleVax Drug Candidate Pipeline

Drug Candidate Pipeline (SEC EDGAR)

HilleVax has booked fair market value investment of $158 million in convertible promissory notes from investors including Frazier Life Sciences and Takeda Vaccines.

HilleVax' Market & Competition

According to a 2021 market research report by Mordor Intelligence, the global market for treating infectious enteritis is forecast to grow at a CAGR of almost 4.9% through 2025.

Key elements driving this expected growth are a growing population with irritable bowel syndrome and diarrhea through a variety of means, including foodborne sources.

Also, it is estimated that 15% of the U.S. population in 2017 was affected in some way by a foodborne illness.

Major competitive vendors that provide or are developing related treatments include BioNTech (BNTX), CSL Behring, GlaxoSmithKline (GSK), Merck (MRK), Moderna (MRNA), Pfizer (PFE), Sanofi (SNY), and Takeda (TAK).

HilleVax Financial Status

The firm's recent financial results are typical of a clinical stage biopharma in that they feature no revenue and significant R&D and G&A expenses associated with its development efforts.

Below are the company's financial results for the past two calendar years:

HilleVax Statement of Operations

Statement of Operations (SEC EDGAR)

As of December 31, 2021, the company had $124.6 million in cash and $69.6 million in total liabilities (ex-convertible promissory notes).

HilleVax IPO Details

HilleVax intends to raise $100 million in gross proceeds from an IPO of its common stock, although the final figure may differ.

No existing shareholders have indicated an interest to purchase shares at the IPO price.

Management says it will use the net proceeds from the IPO as follows:

to fund the clinical development of HIL-214, including certain manufacturing activities, and the remainder for working capital and general corporate purposes.

We may also use a portion of the remaining net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets, although we have no current agreements, commitments or understandings to do so.


Management's presentation of the company roadshow is not available.

Regarding outstanding legal proceedings, management says the firm is not currently a party to any material proceedings.

Listed bookrunners of the IPO are JPMorgan, SVB Leerink, Stifel, and Guggenheim Securities.

Commentary About HilleVax's IPO

HLVX is seeking public investment capital to fund advancement of its program trials.

The firm's lead candidate, HIL-214, is in Phase 2 trials across all four age ranges and is preparing to enter Phase 3 trials for adults between 18 and 59 years old.

The market opportunity for treating acute gastroenteritis is expected to grow at a moderate rate of growth in the coming years.

The company has a major pharma firm collaboration with Takeda Pharmaceuticals through its in-licensing relationship.

Management plans to seek commercialization partners for HIL-214 outside the United States.

The company's investor syndicate includes Takeda and notable healthcare venture investor Frazier Life Sciences.

JPMorgan is the lead underwriter and IPOs led by the firm over the last 12-month period have generated an average return of negative (38.8%) since their IPO. This is a lower-tier performance for all major underwriters during the period.

HLVX is a promising mid-stage firm with top tier investment backing, so the IPO could be interesting for patient life science investors.

But the company relies heavily on its in-license from Takeda, so an important risk factor, above and beyond trial risks, is if that license was terminated.

I'll provide a final opinion when we learn more information about the IPO from management.

Expected IPO Pricing Date: To be announced.

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.


Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Investing in new issues can be a volatile and opaque endeavor. My research is focused on identifying quality companies at a reasonable price, but I’m wrong sometimes. I analyze fundamental company performance and my conclusions may not be relevant for first-day or early new issue trading activity, which can be highly volatile and unrelated to company fundamentals. This report is intended for educational purposes only and is not financial, legal or investment advice. The information referenced or contained herein may change, be in error, become outdated and irrelevant, or removed at any time without notice. You should perform your own research for your particular financial situation before making any decisions. Investing in new issues is subject to significant volatility and risk of loss.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.